JP2019507791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507791A5 JP2019507791A5 JP2018547929A JP2018547929A JP2019507791A5 JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5 JP 2018547929 A JP2018547929 A JP 2018547929A JP 2018547929 A JP2018547929 A JP 2018547929A JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- dihydroxybutan
- sulfonamide
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078242A JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307348P | 2016-03-11 | 2016-03-11 | |
| US62/307,348 | 2016-03-11 | ||
| PCT/US2017/021570 WO2017156270A1 (en) | 2016-03-11 | 2017-03-09 | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Division JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507791A JP2019507791A (ja) | 2019-03-22 |
| JP2019507791A5 true JP2019507791A5 (enExample) | 2020-04-30 |
| JP6883917B2 JP6883917B2 (ja) | 2021-06-09 |
Family
ID=59789863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547929A Expired - Fee Related JP6883917B2 (ja) | 2016-03-11 | 2017-03-09 | 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤 |
| JP2021078242A Active JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Active JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10772886B2 (enExample) |
| EP (1) | EP3426253A4 (enExample) |
| JP (2) | JP6883917B2 (enExample) |
| CN (2) | CN113893252A (enExample) |
| AU (1) | AU2017231832B2 (enExample) |
| BR (1) | BR112018068393A2 (enExample) |
| CA (1) | CA3017345A1 (enExample) |
| CO (1) | CO2018010880A2 (enExample) |
| MX (1) | MX386771B (enExample) |
| WO (1) | WO2017156270A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| WO2019055509A1 (en) * | 2017-09-12 | 2019-03-21 | Ardea Biosciences, Inc. | INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS |
| US11136315B2 (en) | 2018-01-11 | 2021-10-05 | Medshine Discovery Inc. | CXCR2 antagonist |
| WO2021004531A1 (zh) * | 2019-07-11 | 2021-01-14 | 南京明德新药研发有限公司 | 一种cxcr2拮抗剂的晶型及其应用 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| TW202210068A (zh) * | 2020-06-05 | 2022-03-16 | 美商雅力思提雅治療公司 | 用於治療家族性地中海型發熱病的cxcr-2抑制劑 |
| WO2022162021A1 (en) * | 2021-01-27 | 2022-08-04 | Astrazeneca Ab | Verinurad compositions and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| KR100883476B1 (ko) | 2004-01-30 | 2009-02-16 | 쉐링 코포레이션 | Ｃｘｃ-케모킨 수용체 리간드의 결정성 다형체 |
| BRPI0514735B8 (pt) | 2004-08-28 | 2021-05-25 | Astrazeneca Ab | derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina. |
| AU2008206231A1 (en) * | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| EP2203432A4 (en) | 2007-09-21 | 2011-04-27 | Glaxosmithkline Llc | PROCESSING METHOD |
| US20090093548A1 (en) | 2007-10-05 | 2009-04-09 | Mutual Pharmaceutical Company, Inc | Colchine compositions and methods |
| CA2706883A1 (en) | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
| KR20110014141A (ko) | 2008-03-20 | 2011-02-10 | 카롤러스 테라퓨틱스, 인코포레이티드 | 염증을 치료하는 방법 |
| CN102159555A (zh) | 2008-07-16 | 2011-08-17 | 阿斯利康(瑞典)有限公司 | 嘧啶基氨磺酰衍生物及其治疗趋化因子介导的疾病的用途 |
| MX2011003328A (es) | 2008-10-06 | 2011-06-20 | Carolus Therapeutics Inc | Metodos para tratar inflamacion. |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| US20110256130A1 (en) | 2008-12-01 | 2011-10-20 | Joshua Robert Schultz | Methods of treating inflammatory disorders |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
| MX2012003514A (es) | 2009-09-23 | 2012-04-19 | Carolus Therapeutics Inc | Metodos para tratamiento de inflamaciones. |
| WO2011116245A2 (en) | 2010-03-19 | 2011-09-22 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| WO2012007748A1 (en) | 2010-07-13 | 2012-01-19 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| EP2608672B1 (en) * | 2010-08-23 | 2020-12-16 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| PH12014500107A1 (en) | 2011-07-12 | 2014-03-03 | Astrazeneca Ab | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
| JP2015528001A (ja) | 2012-07-11 | 2015-09-24 | ティッシュテック，インク． | Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法 |
| EP3220951A1 (en) | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20180221312A1 (en) | 2016-03-11 | 2018-08-09 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating disorders |
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| WO2019055509A1 (en) | 2017-09-12 | 2019-03-21 | Ardea Biosciences, Inc. | INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS |
-
2017
- 2017-03-09 CN CN202111152242.9A patent/CN113893252A/zh active Pending
- 2017-03-09 MX MX2018010946A patent/MX386771B/es unknown
- 2017-03-09 EP EP17764095.0A patent/EP3426253A4/en not_active Withdrawn
- 2017-03-09 AU AU2017231832A patent/AU2017231832B2/en not_active Ceased
- 2017-03-09 US US15/516,465 patent/US10772886B2/en not_active Expired - Fee Related
- 2017-03-09 BR BR112018068393A patent/BR112018068393A2/pt not_active Application Discontinuation
- 2017-03-09 WO PCT/US2017/021570 patent/WO2017156270A1/en not_active Ceased
- 2017-03-09 CN CN201780029205.4A patent/CN109152780B/zh active Active
- 2017-03-09 JP JP2018547929A patent/JP6883917B2/ja not_active Expired - Fee Related
- 2017-03-09 CA CA3017345A patent/CA3017345A1/en active Pending
-
2018
- 2018-10-10 CO CONC2018/0010880A patent/CO2018010880A2/es unknown
-
2021
- 2021-05-05 JP JP2021078242A patent/JP7126014B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507791A5 (enExample) | ||
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP6532878B2 (ja) | 組合せ医薬 | |
| BR0309670A (pt) | Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo | |
| US20110046119A1 (en) | Therapeutic treatment | |
| JP2005502643A (ja) | 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 | |
| JP2015535247A5 (enExample) | ||
| JP2012184234A5 (enExample) | ||
| KR20150046039A (ko) | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 | |
| JP2014507476A (ja) | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 | |
| JP2013528655A5 (enExample) | ||
| BR112015010063A2 (pt) | método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo | |
| JP2014532726A5 (enExample) | ||
| US20210260025A1 (en) | Capsid assembly modulator dosing regimen | |
| JP2023510719A (ja) | コロナウイルス感染症の治療方法 | |
| MA46268A (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| RU2014115733A (ru) | Новая соль и медицинское применение | |
| JP2013087119A5 (enExample) | ||
| JP2019530711A5 (enExample) | ||
| JP7332589B2 (ja) | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ | |
| JPWO2006104086A1 (ja) | 血栓症治療剤 | |
| JP2015526504A5 (enExample) | ||
| CN1681533A (zh) | 用于治疗动脉硬化的药用组合物 |